Biotech grants in the Netherlands

Closed

Funds clinical and pre-clinical research that pins down the causes of, and builds better diagnostics and treatments for, medical conditions that are common but poorly understood, such as ME/CFS, autism, gynaecological diseases and low back pain.

Closed

Funds beyond-proof-of-concept innovations that make infectious-disease prevention, treatment or diagnostics cheaper, more accessible or better suited to sub-Saharan Africa.

Closed

Pays biomedical New Approach Methodology developers a fixed EUR 300,000 lump-sum grant to validate animal-free testing methods and prepare them for regulatory use.

Closed

Funds one project mining research cohorts and biobanks to find causal links between infections and non-communicable diseases, aimed at new vaccines, diagnostics and early treatments.

Closed

Funds research into how environmental exposures interact with genetic and lifestyle factors to cause cancer in children, adolescents and young adults.

Closed

Funds AI and digital-twin tools that speed up bio-based manufacturing — from biorefinery process control to predicting biosynthesis pathways.

Closed

Funds a full-scale flagship biorefinery that turns separately-collected urban bio-waste into higher-value bio-based products instead of compost or biomethane.

Closed

Funds the advancement of existing vaccine candidates against one named epidemic-prone virus, from lab testing through to a first human safety trial.

Closed

Funds research into new tools and conversion routes that turn low-value forest residues into bio-based chemicals, materials or products beyond bioenergy.

Open

Pays Dutch SME representative bodies to make their members' employee commuting greener.

Between cycles

Funds Dutch firms developing high-risk new products or processes through repayable government loans covering project costs.

Between cycles

Funds Dutch SME teams doing joint R&D to develop or renew products, processes or services.

Between cycles

Offers Dutch companies and professionals tax credits to offset payroll costs for qualifying technical and research projects.

Closed

Pays Trade and Innovate NL network members to run export-support activities for Dutch firms.

Open

Funds a genuinely new experimental or computational approach to finding the cause of a rare genetic disorder, where the current state of the art falls short.

Open

Funds small, high-risk exploratory research into reconstructive transplantation and vascularized composite allotransplantation for wounded Service Members and Veterans.

Open

Pays an equity-free cash prize to the top healthcare startup pitching live at WHX Tech's Xcelerate competition in Dubai.

Open

Funds theory and method development on how genetic and non-genetic factors together produce variation in complex traits, tested against large existing datasets.

Open

Funds investigator-led type 1 diabetes research partnerships across preclinical discovery, treatment, and translational priorities.

Open

Funds new analysis of clinical, genomic, environmental and registry data that already exists, to sharpen who is at risk of cancer and what happens to them.

Open

Funds the development and hard technical validation that turns a working cancer research technology into one other laboratories will actually adopt.

Open

Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.

Open

Funds the same reanalysis of already-collected cancer data on a smaller, exploratory footing, for teams that do not need a full research project award.

Open

Funds exploratory studies of the ethical, legal and social consequences of human genetics, especially where a technology or a use of genomic data is new.